紫杉醇及其衍生物在局部进展期乳腺癌新辅助化疗中的临床疗效分析.doc

《紫杉醇及其衍生物在局部进展期乳腺癌新辅助化疗中的临床疗效分析.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、紫杉醇及其衍生物在局部进展期乳腺癌新辅助化疗中的临床疗效分析【摘耍】目的：分析紫杉醇及其衍生物多西紫杉醇联合毗柔比星和环磷酰胺方案在局部进展期乳腺癌的新辅助化疗中的临床疗效和毒副反应。方法：选取2011年1月-2013年12月本院乳腺外科共分组完成新辅助化疗的73例进展期乳腺癌患者（HB-TITC期），将英随机分为两组：紫杉醇组29例，多西紫杉醇组44例，均联合毗柔比星和坏磷酰胺进行化疗;两组新辅助化疗均以21d为一疗程，共完成4〜6个疗程。观察比较两组患者的化疗疗效及毒副反应。结果：经化疗后，多西紫杉醇组的完全缓解率40.91%明显高于紫杉醇组的17.

2、24%,总有效率93.18%明显高于紫杉醇组的72.41%,差异均有统计学意义（卩0.05）。多西紫杉醇组中骨髓抑制和恶心呕吐症状发生率明显高于紫杉醇组，差异均有统计学意义（P0.05）。结论：多西紫杉醇联合毗柔比星和环磷酰胺针对局部进展期乳腺癌的新辅助化疗的临床疗效比紫杉醇更显著，然而骨髓抑制和恶心呕吐副反应明显，但均可预防控制。【关键词】多西紫杉醇；紫杉醇；进展期乳腺癌；临床疗效；毒副反应ClinicalCurativeEffectAnalysisofPaclitaxelandItsDerivativeinLocallyAdvancedBreastC

3、ancerPatientswithNeoadjuvantChemotherapy/DENGJiang-bo,LUOHuo-ying,WUJia-bao.//MedicalInnovationofChina,2016,13(06)：055-058【Abstract]Objective：ToanalyzetheclinicalefficacyandtoxicityofPaclitaxelanditsderivative(Docetaxel)combinedwith卩irarubicinHydrochlorideandCyclophosphamidein1oc

4、al1yadvancedbreastcancerpatientswithneoadjuvantchemotherapy.Method:Atotalof73patientswithlocallyadvaneedbreastcancer(IIB-IIIC)whocompletedthenewadjuvantchemotherapyadmittedtobreastsurgeryinourhospitalwereselectedanddividedintothe卩aclitaxelgroupfor29casesandtheDocetaxelgroupfor44c

5、ases.ThetwogroupswerecombinedwithPirarubicinHydrochlorideandCyc1ophosphamideforchemotherapy.Neoadjuvantchemotherapyhadfour-sixcycles,21daysforacourseoftreatment.Theclinicalefficacyandtoxicityofneoadjuvantchemotherapybetweenthetwogroupswereobservedandcompared.Result：Afterchemother

6、apytheclinicalcompleteremissionrateandtotaleffectiverateofDocetaxelgroupwere40.91%and93.18%,whichweresignificantlyhigherthan17.24%and72.41%ofthe卩aclitaxelgroup,thedifferenceswerestatisticallysignificant(P0.05)・Theincidenceratesofbonemarrowsuppressionandnausea且ndvomitinginDocetaxe

7、lgroupweresignificantlyhigherthanthoseinthePaclitaxelgroup,thedifferenceswerestatisticallysignificant(卩0.05).Conclusion：TheclinicalefficacyofDocetaxelcombinedwithPirarubicinHj^drochlorideandCyclophosphamideinlocallyadvancedbreastcancerpatientswithneoadjuvantchemotherapyissignific

8、antlybet.terthanPaclitaxel,but.thebonema